SEC Form 4 · accession 0001209191-17-022762
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick W Driscoll
Officer — Chief Financial Officer
Period of report
Mar 23, 2017
Accepted (ET)
Mar 24, 2017 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 23, 2017 | M | 3,000 | $7.8861 | A | 10,777 | D | |
| Common Stock | Mar 23, 2017 | S | 3,000 | $23.00 | D | 7,777 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $7.8861 | Mar 23, 2017 | M | 3,000 | D | — | May 19, 2023 | Common Stock | 3,000 | 102,300 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016.
- F21/4 of the shares subject to the option vest one year after May 20, 2013, with 1/48th of the shares vesting monthly thereafter over the next 3 years.